In the seven years since the first commercially available carbon-plated marathon shoe rewrote the men's two-hour conversation, the running medicine community has been quietly building a parallel record of bone stress injuries. A new evidence review compiled by sports medicine clinicians at three university hospital networks and published in the Journal of Sports Sciences this week sets out, for the first time, a consolidated read on the relationship between super shoes and metatarsal and navicular stress reactions. The headline is less alarmist than the running internet's consensus, but is also more pointed than the manufacturers have publicly admitted: the shoes do appear to shift load patterns in ways that, for a subset of runners, raise the risk of mid-foot injuries.
The review pools data from 14 prospective studies and seven retrospective case series, covering more than 6,200 recreational and elite runners between 2019 and 2026. The headline injury figure is that runners using carbon-plated shoes for at least 30 percent of their weekly mileage were 1.6 times more likely to report a bone stress injury than those running in conventional foam-based trainers. The signal is concentrated in the second and third metatarsals and the navicular, with the calcaneus and tibia showing little change. That mid-foot pattern matches what podiatrists at three of the largest US marathon medical tents have been quietly flagging since 2022.
The biomechanical mechanism the authors propose has settled into a working consensus. The carbon plate stiffens the longitudinal axis of the shoe and reduces metatarsal-phalangeal joint flexion, which lowers the effective work the calf and intrinsic foot muscles do over a stride. That same stiffening forces a higher proportion of the loading impulse through the dorsal midfoot rather than spreading it through the toes, and the magnitude of that loading rises further as midsole stack heights increase and as the foam under the plate gets more compliant. In other words: the same property that makes the shoes feel propulsive at the front of the stride is also why, on the wrong foot, the load arrives at the navicular more abruptly than the runner is used to.
The good news for the average reader is that the absolute risks remain small. Even in the most exposed cohort the reviewers studied, the cumulative incidence of confirmed metatarsal or navicular bone stress injuries over a marathon training cycle was 3.4 percent, against 2.1 percent in conventional shoes. The differential is real, but a long way short of the social-media impression that super shoes are a foot-fracture machine. The risk concentrates in runners who switch over abruptly, run mostly in the shoes during high-mileage blocks, and have either historic bone stress reactions or low energy availability already on their record. The authors are explicit that the runners who keep super shoes for race day and key sessions, and rotate other shoes for everyday training, do not show a meaningful elevation in risk.
The clinical recommendations the review hands down are conservative and likely to feel familiar to careful coaches. Carbon-plated shoes should be introduced gradually and used for no more than half of weekly mileage during a marathon build-up; runners returning from any prior bone stress reaction should stay out of them entirely until cleared; and a midfoot-loaded gait or a known low-energy availability profile should both push the rotation toward less aggressive footwear. The authors close with a call for manufacturers to publish their internal testing data on plate stiffness and bending profiles, which would let clinicians match shoe characteristics to athlete biomechanics. None of that is news to the better-resourced training groups, but for the recreational runner who has only ever known one super shoe, it is the most useful summary the medical literature has yet produced.